title: Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
authors.forename: N
authors.initials: N
authors.lastname: Gaspersic
authors.forename: I
authors.initials: I
authors.lastname: Sersa
authors.forename: V
authors.initials: V
authors.lastname: Jevtic
authors.forename: M
authors.initials: M
authors.lastname: Tomsic
authors.forename: S
authors.initials: S
authors.lastname: Praprotnik
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D000069285:Infliximab; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab